A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE β0-THALASSEMIA
Latest Information Update: 14 Jul 2023
At a glance
- Drugs Glutamine (Primary)
- Indications Beta-thalassaemia; Sickle cell anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Emmaus Medical
- 13 Jul 2023 According to an Emmaus Life Sciences, Inc media release, the company has received marketing authorization from the Oman Ministry of Health for the commercial distribution and sale of Endari (L-glutamine oral powder) in the country to treat sickle cell disease in patients five years of age and older.
- 14 Dec 2021 According to an Emmaus medical media release, post hoc analysis from this study were presented at the 63rd American Society of Hematology Annual Meeting & Exhibition
- 14 Dec 2021 Results of post hoc analysis from this study presented in an Emmaus medical media release.